The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term responders to everolimus: A subgroup analysis of the sector study.
Philippe Barthelemy
Honoraria - Novartis
Bernard Escudier
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis; Pfizer
Florence Joly
Consultant or Advisory Role - Novartis (I)
Lionnel Geoffrois
Consultant or Advisory Role - Novartis
Brigitte Laguerre
Honoraria - Novartis
Nadine Houede
No relevant relationships to disclose
Marine Gross-Goupil
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Vano Yann-Alexandre
Honoraria - Novartis
Olivier Lucidarme
No relevant relationships to disclose
François Bidault
Consultant or Advisory Role - Novartis
Nadia Kelkouli
Employment or Leadership Position - Novartis
Stephane Oudard
Consultant or Advisory Role - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda
Honoraria - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda